Description
Tap (Tapentadol) 200 mg
Tap contains tapentadol, an opioid analgesic used for the treatment of pain. It is a prescription medicine with centrally acting effects and recognised risks typical of opioid medicines.
Active Ingredient and Medicine Class
The verified active ingredient is tapentadol. It belongs to the class of opioid analgesics and is also described as a dual-mechanism analgesic with µ-opioid receptor agonist activity and noradrenaline reuptake inhibition.
Established Medical Uses
Regulatory product information for tapentadol tablets supports use in the management of moderate to severe pain. Published reviews describe its use in acute and chronic pain, including pain with neuropathic features. The exact approved indications vary by country and formulation.
How It Works
Tapentadol relieves pain through two complementary actions: it activates opioid receptors in the central nervous system and reduces reuptake of noradrenaline, which can strengthen descending pain-inhibiting pathways. This combined mechanism helps explain its analgesic effect.
Important Safety Information
Tapentadol should not be used in people with hypersensitivity to tapentadol, and opioid-related precautions apply. Important risks include respiratory depression, addiction, abuse and misuse, and potentially severe interactions with benzodiazepines, alcohol, other opioids, and other central nervous system depressants. Regulatory information also warns about serotonin syndrome when used with serotonergic medicines such as SSRIs, SNRIs, MAOIs, tricyclic antidepressants, and triptans.
Possible Side Effects
Common adverse effects reported with tapentadol include nausea, constipation, vomiting, dizziness, fatigue, and somnolence. Serious reactions can include life-threatening respiratory depression, marked sedation, dependence, and serotonin syndrome.
Scientific Evidence
PubMed-indexed reviews describe tapentadol as an analgesic with dual MOR-NRI activity and a safety profile that may produce fewer gastrointestinal adverse effects than some classical opioids. However, the literature also emphasizes that tapentadol remains an opioid with clinically important safety limitations and interaction risks.
Medical Information Notice
This summary is an educational overview based on sources available at the time of review and does not replace the official patient leaflet, prescribing information, or assessment by a qualified healthcare professional.
Medical Sources
- DailyMed / FDA — TAPENTADOL tablets, for oral use: official prescribing information
- Laura E Gressler et al. — “Serotonin Syndrome in Tapentadol Literature: Systematic Review of Original Research” — J Pain Palliat Care Pharmacother (2017) — PubMed
